F-4660 Fasudil, Monohydrochloride Salt, >99%

Related Terms : [HA-1077, Monohydrochloride Salt] [1-(5-Isoquinolinesulfonyl)homopiperazine, Monohydrochloride Salt] [Eril] [AT-877]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 250 mg
  • 38
  • 34
  • 28
  • 4,000
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 51
  • 46
  • 38
  • 5,400
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 74
  • 67
  • 56
  • 7,900
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 129
  • 117
  • 98
  • 13,700
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 262
  • 238
  • 199
  • 27,800
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 475
  • 432
  • 362
  • 50,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 327.83
  • C14H17N3O2S•HCl
  • [105628-07-7]
  • M.I. 12: 3980
  • M.I. 14: 3942

Storage: Store at or below -20 ºC. Solubility: Very soluble in water, up to about 200 mg/mL ; soluble in DMSO up to about 95 mg/mL; not soluble in ethanol; addition of an aqueous solution of this monohydrochloride salt into a buffer solution may significantly alter its solubility. Disposal: A.

  • Nomenclature. Two names have been widely used for this compound, "HA-1077" and "Fasudil". These names have been variously and inconsistently applied to the free base, the monohydrochloride salt (the only form that LC Labs currently sells) and the dihydrochloride salt forms.
  • The monohydrochloride salt is the form used to prepare formulations of this drug for clinical use. Note that the solubility properties of the mono- and di-HCl salts are different.
  • Kinase inhibitor; has antivasospastic properties. -- Asano, T., et al. "Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinases." Br. J. Pharmacol. 98: 1091-1100 (1989). -- Sasaki, Y. and Sasaki, Y. "Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilator." Biochem. Biophys. Res. Commun. 171: 1182-1187 (1990). -- Seto, M., et al. "Effects of HA 1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle." Eur. J. Pharmacol. 195: 267-272 (1991). -- Shibuya, O., et al. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs. Acta Neurochir. 90: 53 (1988). -- Shirotani, M. et al. "A new type of vasodilator, HA 1077, an isoquinoline derivative, inhibits proliferation of bovine vascular smooth muscle cells in culture." J. Pharmacol. Exp. Ther. 259: 738-744 (1991). -- Swärd, K. et al. "Inhibition of Rho-associated kinase blocks agonist-induced Ca2+ sensitization of myosin phosphorylation and force in guinea-pig ileum." J. Physiol. 522: 33-49 (2000). -- Davies, S.P. et al. "Specificity and mechanism of action of some commonly used protein kinase inhibitors." Biochem. J. 351: 95-105 (2000).
  • Potencies for inhibition of various kinases by Fasudil:

    Enzyme

    IC50

    Ki

    Reference

    Rho-associated Kinase II

    1.9 µM

     

    Davies, S.P. et al.

    Protein Kinase C-Related Kinase 2

    4 µM

     

    Davies, S.P. et al.

    Mitogen- and Stress-Activated Protein Kinase 1

    5 µM

     

    Davies, S.P. et al.

    Mitogen Activated Protein Kinase-Activated Protein Kinase 1b

    5 µM

     

    Davies, S.P. et al.

    Rho-associated Kinase

    10.7 µM

     

    Swärd, K. et al.

    Myosin Light Chain Kinase

    95.2 µM

     

    Swärd, K. et al.

    Protein Kinase C

    425 µM

     

    Swärd, K. et al.

    Cyclic AMP-Dependent Protein Kinase

     

    1.6 µM

    Asano, T. et al.

    Cyclic GMP-Dependent Protein Kinase

     

    1.6 µM

    Asano, T. et al.

    Myosin Light Chain Kinase

     

    36 µM

    Asano, T. et al.

  • This monohydrochloride salt form is the active ingredient in drug formulations marketed in Japan to treat cerebral vasospasm following surgery for subarachnoid hemorrhage and associated cerebral ischemic symptoms. Zhao, J. et al. "Effect of Fasudil Hydrochloride, a Protein Kinase Inhibitor, on Cerebral Vasospasm and Delayed Cerebral Ischemic Symptoms After Aneurysmal Subarachnoid Hemorrhage." Neurologia Medico-Chirurgica 46: 421-428 (2006). Also, the monohydrochloride form has been or presently is in human clinical trials for treatment of acute cerebral thrombosis, subarachnoid hemorrhage, and angina pectoris.
  • Related CAS numbers: 103745-39-7 for fasudil free base and 203911-27-7 for HA-1077 dihydrochloride salt.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
109